Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Webcasts|July 22, 2021

Detection of Replication Competent Viruses in Viral Vector Product

Author(s)Charles River

Thursday July 22, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST Learn how to detect replication competent virus in your gene therapy and what regulators are looking for when testing viral vectors.

Register Free: https://www.biopharminternational.com/bp_w/viruses

Event Overview:

With the development of viral vector products comes the challenge of ensuring viral safety without inactivating or removing product. One of the major risks associated with production of viral vectors is the generation of replication-competent viruses, such as adenovirus and lentivirus.

This webcast will discuss the following topics:

  • New guidance issued by the European Pharmacopeia and FDA concerning the testing of these vectors for replication competent viruses
  • Why robust detection assays are necessary to screen these products to ensure safety
  • Newly established platform assays for adenovirus, adeno-associated virus, retrovirus, and lentivirus-based vectors

Key Learning Objectives:

  • Understand how replication-competent virus are generated during the vector production process and why testing for these is important.
  • Understand the regulatory guidance concerning testing for replication-competent viruses.
  • Learn how assays for detection of replication-competent viruses work.

Who Should Attend:

  • Scientists, research staff, and managers responsible for the development of gene-therapy viral vector products

Speakers

Matthew Pennington, PhD
Scientist 2, Virology, Biologics Solutions
Charles River

Matthew Pennington completed his undergraduate work at Seton Hall University and received adoctoral degree from Cornell University in immunology and infectious disease, where he worked on the pathogenesis, treatment, and development of new assays to study herpesviruses. After completing post-doctoral work at Harvard Medical School studying adenovirus immunology, Matt joined Charles River as a scientist in the virology department of biologics testing solutions in September 2019. He has principally been focused on developing Charles River Labs’ cell and gene therapy testing capabilities, including designing assays to detect replication competent viruses in viral vector products. His peer-reviewed articles have been published in Journal of Virology, Microorganisms, Viruses, American Journal of Veterinary Research, and others.

Register Free: https://www.biopharminternational.com/bp_w/viruses

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more